MVMuhammad Vazaym

Muhammad Vazaym

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Muhammad Vazaym has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Temporal trends and projections of hypertension with hyperlipidemia-related mortality among US adults, 2000–2035: Insights from CDC WONDER database

    by Saifullah Khan, Muhammad Vazaym, Muhammad Jawad, Nisha Khalid, Pari Kotak, Muhammad Hassan, Muhammad Hussain, Muskan Devi, Muhammad Mubashir, Asma Naz, et al.

  • Trends in Mortality Among Decedents With Coexisting Neoplasms and Cardiac Arrhythmias in the United States, 1999–2024

    by Pari Kotak, Armeen Shahzad, Syed Shayan Ali, Maryam Waqar, Muhammad Vazaym, Muhammad Jawad, Amisha Kumari, Faiz Un Nisa

  • Open Access

    Pulsed field ablation versus thermal ablation for paroxysmal atrial fibrillation: a systematic review and meta-analysis

    by Hassaan Abid, Rithik Khaini, Muhammad Vazaym, Amina Zia Rashid, Bisma Tasawar, Muhammad Jawad, Gaaitri Lohano, Vikash Kumar Karmani, Hussain Abbas, Syed Mohamin Abbas Shah

  • Open Access

    Clevidipine vs. nicardipine in hypertensive crisis: a systematic review and meta-analysis

    by Hassaan Abid, Syed Mohamin Abbas Shah, Amina Zia Rashid, Bisma Tasawar, Rimsha Adnan, Sohana Memon, Gaaitri Lohano, Muhammad Jawad, Muhammad Vazaym, Muhammad Junaid

    Background: Clevidipine and nicardipine are commonly used intravenous calcium channel blockers for the management of hypertensive crises. However, comparative evidence regarding their efficacy and safety remains limited. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials and observational studies comparing intravenous clevidipine and nicardipine in adults with hypertensive crises. The primary outcome was achievement of target blood pressure reduction. Secondary outcomes included medication volume and blood pressure over-reduction. Random-effects models were used, and certainty of evidence was assessed using the GRADE framework. Results: Three studies involving 599 patients were included. Clevidipine and nicardipine demonstrated comparable achievement of target blood pressure reduction (OR 0.96, 95% CI 0.48–1.94; I² = 60%; very low-certainty evidence). Clevidipine was associated with lower odds of blood pressure over-reduction (OR 0.44, 95% CI 0.21–0.93; I² = 0%) and lower medication volume (MD − 258.43 mL, 95% CI − 313.38 to − 203.48 mL; I² = 0%). Conclusion: Clevidipine and nicardipine demonstrated comparable efficacy in achieving target blood pressure reduction in hypertensive crises. Although clevidipine was associated with lower odds of blood pressure over-reduction and lower medication volume, the evidence base was limited and the certainty of evidence for the primary outcome was very low. These findings should be interpreted cautiously and considered hypothesis-generating until confirmed by larger, high-quality randomized controlled trials.

  • Open Access

    Temporal Trends and Demographic Disparities in Abdominal Aortic Aneurysm Mortality Among U.S. Adults Aged ≥ 65 Years, 1999–2024: A Nationwide Population-Based Analysis of CDC WONDER Data

    by Hassaan Abid, Muhammad Jawad, Sohana Memon, Muhammad Vazaym, Gaaitri Lohano, Rimsha Adnan, Muhammad Mohid Haroon, Rithik Khiani

    Background: Abdominal aortic aneurysm (AAA) remains an important cause of cardiovascular mortality in the United States despite advances in screening, surveillance, and aneurysm repair. Contemporary national analyses evaluating long-term AAA mortality trends across demographic and geographic subgroups remain limited, particularly following the COVID-19 pandemic period. Objective: To evaluate temporal trends in AAA-related mortality among U.S. adults aged ≥ 65 years from 1999 to 2024 and characterize demographic and geographic disparities. Methods: A retrospective population-based study was conducted using the CDC WONDER Multiple Cause of Death database. AAA-related deaths were identified using International Classification of Diseases, Tenth Revision (ICD-10) codes I71.3 and I71.4. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated using the 2000 U.S. standard population. Mortality trends were stratified by sex, age, race/ethnicity, census region, and urbanization status. Joinpoint regression analysis was used to estimate annual percent change (APC) and average annual percent change (AAPC). Results: Between 1999 and 2024, a total of 208,476 AAA-related deaths among U.S. adults aged ≥ 65 years were recorded. Overall AAMR declined significantly from 32.61 per 100,000 population in 1999 to 12.17 per 100,000 population in 2024 (AAPC −3.86%; 95% confidence interval [CI]: −4.43 to −3.30; p < 0.001). Mortality rates remained consistently higher among males, adults aged ≥ 85 years, non-Hispanic White individuals, residents of the Midwest, and non-metropolitan populations. Joinpoint analysis demonstrated sustained declines across most demographic groups. Although several subgroups exhibited a temporary plateau in declining mortality trends during the pandemic era, these trend changes did not reach statistical significance. Following 2021, mortality rates resumed a significant downward trend. Conclusions: AAA-related mortality among U.S. adults aged ≥ 65 years declined substantially between 1999 and 2024; however, important demographic and geographic disparities persist. Continued efforts aimed at risk factor reduction, equitable screening access, and preventive vascular care remain essential to further reduce AAA-related mortality among older adults.

  • Open Access

    National Trends and Demographic Disparities in Mortality Involving Co-Recorded Parkinson’s Disease and Dementia in the United States, 1999–2025: A CDC WONDER Analysis

    by Hassaan Abid, Sohana Memon, Vishan Das, Kaneez Fatima, Muhammad Mukhlis, Muhammad Vazaym

    Background: Parkinson’s disease and dementia are major neurodegenerative disorders that substantially contribute to disability, dependency, and mortality worldwide. Although prior CDC WONDER studies have separately evaluated Parkinson’s disease and dementia mortality trends, fewer analyses have examined national mortality patterns in which both conditions are recorded on death certificates simultaneously over extended time periods. Methods: We analyzed U.S. death certificates from 1999 through 2025 using the CDC WONDER Multiple Cause of Death database, identifying deaths among adults aged ≥45 years in which both Parkinson’s disease (ICD-10 G20) and dementia-related codes (F01, F03, G30, G31) were recorded anywhere on the certificate. This operational definition captures co-recorded diagnoses and does not identify clinically confirmed Parkinson’s disease dementia. Age-adjusted mortality rates (AAMRs) per 100,000 were standardized to the 2000 U.S. standard population, a method that controls for shifts in population age structure over time and allows valid temporal comparisons independent of absolute population growth. Joinpoint regression was used to quantify trends. Sensitivity analyses excluded 2025 provisional data and the COVID-19 period (1999–2019). Results: A total of 337,721 deaths were identified. Overall AAMR increased from 5.75 (95% CI: 5.60–5.90) in 1999 to 11.15 (95% CI: 10.98–11.32) in 2025 (AAPC: 2.07; p = 0.002). A sharp transient increase occurred in 2020, attributable to pandemic-related factors including disproportionate COVID-19 mortality among older adults with neurodegenerative conditions, care disruptions, and changes in death-certificate coding practices. Following this pandemic-era peak, AAMRs declined significantly through 2025 and should be interpreted cautiously given provisional data. Males (AAPC: 2.14), non-Hispanic White individuals (AAPC: 2.29), the Midwest region (AAPC: 2.65), and non-metropolitan areas carried the highest mortality burden. Mortality was greatest among adults aged ≥85 years. Conclusion: Population-level death rates involving co-recorded Parkinson’s disease and dementia demonstrated significant temporal changes over the study period, with marked demographic and geographic disparities. These findings reflect death-certificate surveillance data and cannot establish clinical co-occurrence, causal relationships, or individual disease risk.


  • Open Access

    National Trends in Mortality Involving Coronary Artery Disease and Depression in the United States, 1999–2025: A CDC WONDER Analysis

    by Hassaan Abid, Sohana Memon, Vishan Das, Tauseef Hamid, Kaneez Fatima, Muhammad Mukhlis, Muhammad Vazaym, Rithik Khiani

    Background: Coronary artery disease (CAD) and depression frequently coexist and may synergistically worsen outcomes through behavioral, inflammatory, and neuroendocrine mechanisms. However, national mortality trends involving both conditions remain incompletely characterized.Objective: To evaluate temporal trends and demographic disparities in mortality involving CAD and depression in the United States from 1999–2025.Methods: We conducted a retrospective population-based study using the CDC WONDER Multiple Cause of Death database. Adults aged ≥25 years with ICD-10 codes for CAD (I20–I25) and depression (F32, F33, F41.2) listed anywhere on the death certificate were identified. Age-adjusted mortality rates (AAMRs) per 100,000 population were standardized to the 2000 U.S. population. Joinpoint regression was used to estimate annual percent change (APC) and average annual percent change (AAPC), with analyses stratified by age, sex, race/ethnicity, geographic region, urbanization, and state.Results: A total of 85,806 deaths were identified, with an overall average AAMR of 1.42. Mortality declined from 1.81 (95% CI, 1.75–1.87) in 1999 to 1.31 (95% CI, 1.26–1.35) in 2025 (AAPC, −1.38; p=0.002), although rates increased significantly between 2017 and 2020. Mortality was highest among older adults but increased among middle-aged adults (AAPC, 1.10; p<0.001). Males had higher mortality than females. The Midwest had the highest regional burden, while the South showed no significant overall improvement. Mortality increased among Black individuals after 2014 and remained higher in nonmetropolitan areas.Conclusions: Mortality involving CAD and depression declined overall but remained heterogeneous, with persistent racial and geographic disparities and rising mortality among middle-aged adults.

  • Open Access

    Meningitis Mortality in U.S. Adults Aged ≥25 Years: Demographic and Geographic Insights from the CDC WONDER Database (1999–2024)

    by Hassaan Abid, Muhammad Jawad, Muhammad Vazaym, Gaaitri Lohano, Syed Mohamin Abbas Shah, Naveed Ahmed Khan, Abdullah Afridi, Muhammad Mohid Haroon

    Meningitis remains a significant cause of morbidity and mortality in the United States despite advances in vaccination, antimicrobial therapy, and critical care. However, long-term national mortality patterns across demographic and geographic subgroups remain incompletely characterized. This study evaluated temporal trends in meningitis-associated mortality among U.S. adults aged ≥25 years from 1999 to 2024 using the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) Multiple Cause of Death database. Death certificates listing meningitis as either the underlying cause or a contributing cause of death were identified using ICD-10 codes to capture meningitis-associated mortality. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated using the 2000 U.S. standard population. Temporal trends were assessed using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC). Across the study period, meningitis-associated mortality demonstrated an early decline followed by stabilization and more recent increases in several subgroups. AAMRs decreased significantly from 1999 to 2001 (APC: −14.09%; p = 0.0029) and from 2001 to 2013 (APC: −4.74%; p < 0.000001), followed by a significant increase from 2013 to 2024 (APC: 1.78%; p = 0.0059). Despite these later increases, the overall AAPC across the full study period remained significantly negative (AAPC: −2.73%; p < 0.000001). Earlier analyses using shorter observation windows did not demonstrate a statistically significant overall trend; the significance observed in the present analysis reflects the inclusion of extended mortality data through 2024. Mortality rates were consistently higher among males and adults aged ≥65 years. Non-Hispanic Black individuals experienced increasing mortality after 2013, while Hispanic individuals demonstrated a sustained increase across the entire study period. Regional analyses showed recent increases in the Northeast, South, and West, while non-metropolitan areas did not experience statistically significant improvement through 2020. In summary, meningitis-associated mortality among U.S. adults declined significantly during the early study years but has shown stabilization and recent increases in several demographic and geographic subgroups since approximately 2013. Although overall mortality across the full study period remains lower than baseline levels, these emerging disparities highlight the importance of continued surveillance and targeted public health interventions.